aur-201
Gene therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 4, 2022 (NCT06225336)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, passive
ERBB2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06072040 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2023 | Auregen Biotherapeutics, SA, Romo Plastic Surgery |
| NCT06078566 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2023 | Auregen Biotherapeutics, SA, Romo Plastic Surgery |
| NCT06225336 | Phase 1 | Nov 4, 2022 | Auregen Biotherapeutics, SA, Chris O'Brien Lifehouse |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Auregen Biotherapeutics, SA | For profit | 3 | 3 | 2 | 2022 |
| Romo Plastic Surgery | Academic/Hospital | 2 | 0 | 1 | 2023 |
| Chris O'Brien Lifehouse | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1